Scientists Flag Flaws in 85,000-Download Ivermectin Cancer Study as Journal Issues Concern
Updated
Updated · The Conversation · Jul 8
Scientists Flag Flaws in 85,000-Download Ivermectin Cancer Study as Journal Issues Concern
3 articles · Updated · The Conversation · Jul 8
Summary
More than 85,000 downloads helped a June 2026 ivermectin-cancer paper spread rapidly before scientists challenged its methods, conflicts of interest and peer-review process.
No control group and patient self-reports undercut the study’s central claim, leaving no reliable way to separate any effect of ivermectin from conventional cancer treatments patients were also receiving.
The journal has issued an Expression of Concern but has not retracted the paper, even as researchers stress there is still no evidence ivermectin is safe or effective for treating cancer in people.
A 198% jump in online discussion after celebrity endorsements and a doubling of related cancer prescriptions show how quickly weak early findings can shape real-world health decisions.
The episode highlights a broader mismatch: studies can go viral within hours, while the stronger evidence needed to confirm or overturn them often takes months or years.
With unproven cancer 'cures' going viral, is the real sickness our system for sharing scientific truth?
When facing a terminal diagnosis and crushing costs, is trying an unproven viral drug a reckless gamble?
Celebrities and AI are now giving medical advice. How can patients find truth amid the deadly noise?
"Ivermectin and Mebendazole in Cancer: The 84.4% Benefit Study, Scientific Rebuttal, and the Misinformation Crisis"
Overview
In July 2026, a controversial study claimed that ivermectin and mebendazole provided major benefits for cancer patients, reporting an 84.4% clinical benefit rate. However, the study did not go through peer review and was only released as a preprint, raising immediate concerns. Its methodology relied on self-reported data without independent verification and lacked a control group, making the results unreliable. The authors also had conflicts of interest, as they were connected to the clinic selling these drugs. These flaws led experts to dismiss the findings, highlighting the importance of rigorous scientific standards in medical research.